Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg | ||
Other Sizes |
ln Vitro |
The cell survival of SHSY-5Y cells treated with oxygen-glucose deprivation and reperfusion (OGD/R) is increased by monomethyl lithospermate (5, 10 and 20 μM; 12 h) [1]. After hypoxia and glucose deprivation/reoxygenation, monomethyl lithospermate (20 μM; 12 h) can decrease apoptosis, mitochondrial membrane potential loss, and cell damage in SHSY-5Y cells [1]. In SHSY-5Y cells, monomethyl lithospermate (5, 10 and 20 μM; 12 h) lowers intracellular oxidative stress and reactive oxygen species [1]. In SHSY-5Y cells, monomethyl lithospermate (20 μM; 12 h) can activate PI3K/AKT[1].
|
---|---|
ln Vivo |
In rats with ischemia-reperfusion (IR) 24 hours after middle artery occlusion (MCAO), monomethyl lithospermate (72.4 μM/kg; oral; once daily for 14 days) improves neurological function and reduces the size of the cerebral infarct; it can also lower oxidative stress levels and prevent neuronal apoptosis[1]. Through PI3K/AKT activation, monomethyl lithospermate mitigates ischemia-reperfusion-induced nerve injury [1].
|
Cell Assay |
Immunofluorescence[1]
Cell Types: SHSY-5Y cells Tested Concentrations: 5, 10, and 20 μM Incubation Duration: 12 hrs (hours) Experimental Results: Inhibited the mitochondrial membrane potential (MMOP) collapse and apoptosis of SHSY-5Y cells induced by oxygen and glucose deprivation/ Reoxygenation (OGD/R) treatment. |
References |
[1]. Yang F, et al. Monomethyl lithospermate alleviates ischemic stroke injury in middle cerebral artery occlusion mice in vivo and protects oxygen glucose deprivation/reoxygenation induced SHSY-5Y cells in vitro via activation of PI3K/Akt signaling. Front Pharmacol. 2022 Oct 13;13:1024439.
|
Molecular Formula |
C28H24O12
|
---|---|
Molecular Weight |
552.48
|
CAS # |
933054-33-2
|
SMILES |
C([C@@H]1[C@@H](C2C=CC(O)=C(O)C=2)OC2C(=CC=C(C1=2)/C=C/C(=O)O[C@@H](C(=O)O)CC1C=CC(O)=C(O)C=1)O)(=O)OC
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
---|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.8100 mL | 9.0501 mL | 18.1002 mL | |
5 mM | 0.3620 mL | 1.8100 mL | 3.6200 mL | |
10 mM | 0.1810 mL | 0.9050 mL | 1.8100 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.